GPCR family is a one of those popular drug target in recent years. However, due to its natural of multi-pass transmembrane structure, it is considered as one of most the challenging type to develop therapeutic antibodies. DNA and whole cell immunization are commonly used to generate antibody leads against GPCR target, but the intrinsic feature of these antigens lead to extremely low hit rate. In this webinar, Dr. Li Chen will introduce a mRNAbased immunization, coupled with high throughput hybridoma screening approach, and demonstrate its advantage over traditional approach.

In this webinar, you will learn: 

1. Review of clinical progress for anti-GPCR therapeutic antibody 

2. Integrated solution of therapeutic antibody discovery against GPCR target

3. Case study of anti-GPCR antibody drug candidates 

■ 주제: Integrated Antibody Discovery Solution for Multi-pass transmembrane target 

■ 일정: 2023년 11월 28일(화) 오후 2시-3시 (KST)

■ 등록 링크 : https://www.ibric.org/bric/webinar/tech-all.do?mode=view&id=636&pager.offset=0&pagerLimit=10

■ 문의 : webinar@ibric.org